Abstract
In summary, because folic acid may reduce HCY plasma levels, a new risk factor for CAD, we tested whether an FDA mandate for folic acid fortification of foods would affect plasma HCY among 2,755 subjects studied angiographically over 4 years and at high risk of incident coronary events. Plasma HCY declined by 2 μmol/L, and the percentage of patients with high-risk HCY decreased by 1/3 in temporal association with implementation of the FDA rule.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
